Key Insights
The European companion diagnostics market is experiencing robust growth, projected to reach €1.29 billion in 2025 and maintain a Compound Annual Growth Rate (CAGR) of 9.23% from 2025 to 2033. This expansion is fueled by several key factors. The rising prevalence of cancers like lung, breast, and colorectal cancer, coupled with increasing demand for personalized medicine, is a primary driver. Advancements in molecular diagnostics, particularly in technologies such as immunohistochemistry (IHC), polymerase chain reaction (PCR), and next-generation sequencing (NGS), are enabling more precise diagnoses and targeted therapies, thus boosting market demand. Furthermore, favorable regulatory frameworks within the EU supporting the development and adoption of companion diagnostics are contributing to market growth. Germany, the United Kingdom, and France represent the largest national markets within Europe, reflecting their advanced healthcare infrastructure and robust pharmaceutical industries. However, the market also faces challenges. High costs associated with advanced diagnostic technologies can limit accessibility, particularly in regions with less developed healthcare systems. Additionally, the complexity of implementing companion diagnostics into routine clinical practice and ensuring appropriate reimbursement models requires continued attention.
The market segmentation reveals a significant contribution from IHC and PCR technologies, reflecting their established roles in cancer diagnosis. However, the rapidly evolving landscape of gene sequencing and other advanced technologies is expected to drive significant growth in the coming years. Among indications, lung, breast, and colorectal cancers are currently the dominant segments, but the expanding application of companion diagnostics to other cancers like leukemia and melanoma, alongside the development of novel therapies, will further fuel market expansion. Key players like Thermo Fisher Scientific, BioMerieux, Siemens Healthineers, and Roche are actively investing in R&D and strategic partnerships to strengthen their market positions and capitalize on emerging opportunities within the European companion diagnostics market. The forecast period (2025-2033) promises continued growth, shaped by technological advancements, increased awareness of personalized medicine, and supportive regulatory landscapes.

Europe Companion Diagnostics Market: A Comprehensive Report (2019-2033)
This insightful report provides a detailed analysis of the Europe Companion Diagnostics market, offering a comprehensive overview of its current state, future trajectory, and key players. With a study period spanning 2019-2033, a base year of 2025, and a forecast period of 2025-2033, this report is an invaluable resource for stakeholders seeking to understand and capitalize on the growth opportunities within this dynamic sector. The market is projected to reach xx Million by 2033, demonstrating significant growth potential.
Europe Companion Diagnostics Market Market Composition & Trends
The European Companion Diagnostics market is characterized by a moderately concentrated landscape, with key players like Thermo Fisher Scientific Inc, BioMerieux SA, Siemens Healthineers, Abbott Laboratories, Qiagen Inc, F Hoffmann-La Roche AG, Beckman Coulter Inc (Danaher Corporation), and Agilent Technologies holding significant market share. However, the market also features several smaller, specialized companies contributing to innovation. Market share distribution is currently estimated at approximately xx% for the top five players in 2025, reflecting a degree of consolidation. Innovation is driven by advancements in molecular diagnostics, personalized medicine, and the increasing demand for targeted therapies. The regulatory landscape, primarily governed by the European Medicines Agency (EMA), plays a crucial role in shaping market access and product approvals. Substitute products are limited, as companion diagnostics are often intrinsically linked to specific therapies. End-users primarily comprise hospitals, diagnostic laboratories, and research institutions. M&A activity has been moderate but significant, with deal values in recent years averaging xx Million. This reflects a strategic focus on expanding product portfolios and strengthening market positions.
- Market Concentration: Moderately concentrated, with top players holding xx% market share in 2025.
- Innovation Catalysts: Advancements in molecular diagnostics, personalized medicine, and targeted therapies.
- Regulatory Landscape: Primarily governed by EMA, influencing market access and approvals.
- Substitute Products: Limited due to close linkage with specific therapies.
- End-User Profiles: Hospitals, diagnostic laboratories, research institutions.
- M&A Activity: Moderate but significant, with average deal values of xx Million in recent years.

Europe Companion Diagnostics Market Industry Evolution
The Europe Companion Diagnostics market has experienced substantial growth over the historical period (2019-2024), fueled by the rising prevalence of chronic diseases, particularly cancer, the increasing adoption of targeted therapies, and ongoing technological advancements. The market exhibited a Compound Annual Growth Rate (CAGR) of xx% from 2019 to 2024. Technological advancements, such as next-generation sequencing (NGS) and improved immunohistochemistry (IHC) techniques, are continuously improving diagnostic accuracy and efficiency. This is complemented by a growing emphasis on personalized medicine, driving demand for companion diagnostics that guide treatment decisions based on individual patient characteristics. Consumer demand is shifting toward more accurate, faster, and cost-effective diagnostic solutions, pushing innovation and competition within the market. Adoption metrics indicate a steady increase in the utilization of companion diagnostics across various cancer types, with particular growth observed in areas like lung, breast, and colorectal cancer testing. The forecast period (2025-2033) anticipates continued strong growth, projected at a CAGR of xx%, driven by factors such as increasing investment in R&D, expanding regulatory approvals, and the growing adoption of precision medicine.
Leading Regions, Countries, or Segments in Europe Companion Diagnostics Market
Dominant Segments: By Technology, Immunohistochemistry (IHC) and Polymerase Chain Reaction (PCR) currently hold the largest market shares due to their established use and relatively lower costs. Gene sequencing is experiencing rapid growth fueled by technological advancements and expanding applications. By Indication, lung cancer, breast cancer, and colorectal cancer lead, reflecting their high prevalence and the availability of targeted therapies.
Key Drivers (By Technology):
- IHC: Established technology, relatively lower cost, widespread availability.
- PCR: High sensitivity and specificity, versatile applications.
- ISH: Increasingly used for specific genetic targets in oncology.
- Gene Sequencing: Rapid technological advancements, potential for personalized medicine.
Key Drivers (By Indication):
- Lung Cancer: High prevalence, multiple targeted therapies available.
- Breast Cancer: High prevalence, increasing use of targeted therapies and biomarkers.
- Colorectal Cancer: High prevalence, established use of companion diagnostics.
Germany, France, and the UK currently represent the largest national markets, driven by robust healthcare infrastructures, advanced research capabilities, and a high prevalence of target diseases. These countries benefit from strong regulatory support and significant investments in healthcare technology. The growth in these markets is anticipated to continue during the forecast period, driven by increasing adoption of precision oncology and growing healthcare expenditures.
Europe Companion Diagnostics Market Product Innovations
Recent product innovations focus on improving the speed, accuracy, and affordability of companion diagnostics. This includes the development of multiplex assays, which allow the simultaneous testing of multiple biomarkers, and the integration of artificial intelligence (AI) for improved data analysis and interpretation. Advances in NGS technology have enabled more comprehensive genomic profiling, providing crucial information for targeted therapy selection. These innovations are enhancing the clinical utility of companion diagnostics, improving patient outcomes, and driving market growth.
Propelling Factors for Europe Companion Diagnostics Market Growth
Technological advancements in molecular diagnostics, such as NGS and microfluidics, are significantly accelerating the development of more sensitive and specific companion diagnostics. The rising prevalence of chronic diseases, especially cancer, is creating a substantial demand for accurate and timely diagnostic tests to guide personalized treatment strategies. Favorable regulatory support, including streamlined approval processes for innovative CDx, is facilitating market entry and accelerating product adoption. Government funding for research and development of new diagnostic technologies is creating a supportive ecosystem for market expansion.
Obstacles in the Europe Companion Diagnostics Market Market
Regulatory hurdles, including stringent approval processes and complex reimbursement schemes, can slow down market entry for new companion diagnostics. Supply chain disruptions and shortages of critical reagents and components can impact the availability and affordability of testing services. Intense competition among established players and emerging companies can lead to price pressure and reduced profit margins. These challenges can hinder market growth and limit the accessibility of companion diagnostics.
Future Opportunities in Europe Companion Diagnostics Market
Emerging opportunities lie in the development of liquid biopsies, which offer a minimally invasive approach to cancer diagnostics, and the integration of AI and machine learning for improved diagnostic accuracy and efficiency. Expansion into new therapeutic areas beyond oncology, such as infectious diseases and autoimmune disorders, holds significant potential for market growth. Increased demand for point-of-care diagnostics will enable faster diagnosis and personalized treatment.
Major Players in the Europe Companion Diagnostics Market Ecosystem
- Thermo Fisher Scientific Inc
- BioMerieux SA
- Siemens Healthineers
- Abbott Laboratories
- Qiagen Inc
- F Hoffmann-La Roche AG
- Beckman Coulter Inc (Danaher Corporation)
- Agilent Technologies
Key Developments in Europe Companion Diagnostics Market Industry
August 2022: BD (Becton, Dickinson, and Company) partnered with Labcorp to develop flow cytometry-based companion diagnostics for cancer and other diseases, expanding the scope of available tests and potentially increasing market reach.
May 2022: Agilent Technologies Inc. received EU CE-IVD marking for its PD-L1 IHC 22C3 pharmDx, expanding its companion diagnostic offerings in cervical cancer and providing a valuable tool for treatment selection.
May 2022: Illumina, Inc. added a companion diagnostic indication to its TruSight Oncology Comprehensive (EU) test, further strengthening its position in the market and potentially increasing market penetration.
April 2022: Amoy Diagnostics Co. entered a master collaboration agreement with AstraZeneca for developing and commercializing companion diagnostic assays in China, Europe, and Japan, signifying a significant move towards broader global accessibility of companion diagnostics and increased market competition.
Strategic Europe Companion Diagnostics Market Market Forecast
The Europe Companion Diagnostics market is poised for substantial growth over the forecast period, driven by technological innovations, increasing healthcare spending, and the growing adoption of personalized medicine. The continued development of advanced diagnostic technologies, including liquid biopsies and AI-powered solutions, will further expand market opportunities. The increasing prevalence of chronic diseases and the ongoing shift toward precision medicine are expected to fuel demand for accurate and timely companion diagnostic tests, contributing to the market’s sustained growth trajectory.
Europe Companion Diagnostics Market Segmentation
-
1. Technology
- 1.1. Immunohistochemistry (IHC)
- 1.2. Polymerase Chain Reaction (PCR)
- 1.3. In-situ Hybridization (ISH)
- 1.4. Gene Sequencing
- 1.5. Other Technologies
-
2. Indication
- 2.1. Lung Cancer
- 2.2. Breast Cancer
- 2.3. Colorectal Cancer
- 2.4. Leukemia
- 2.5. Melanoma
- 2.6. Other Indications
Europe Companion Diagnostics Market Segmentation By Geography
- 1. Germany
- 2. United Kingdom
- 3. France
- 4. Italy
- 5. Spain
- 6. Rest of Europe

Europe Companion Diagnostics Market REPORT HIGHLIGHTS
Aspects | Details |
---|---|
Study Period | 2019-2033 |
Base Year | 2024 |
Estimated Year | 2025 |
Forecast Period | 2025-2033 |
Historical Period | 2019-2024 |
Growth Rate | CAGR of 9.23% from 2019-2033 |
Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Rising Demand for Personalized Medicine and Targeted Therapy; Rise in Biomarker Discovery; Rising Prevalence of Chronic Diseases
- 3.3. Market Restrains
- 3.3.1. High Cost of Drug Development and Associated Clinical Trials; High Reimbursement Issues Associated with Personalized Medicines
- 3.4. Market Trends
- 3.4.1. Immunohistochemistry Segment is Estimated to Register Significant Growth over the Forecast Period.
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Europe Companion Diagnostics Market Analysis, Insights and Forecast, 2019-2031
- 5.1. Market Analysis, Insights and Forecast - by Technology
- 5.1.1. Immunohistochemistry (IHC)
- 5.1.2. Polymerase Chain Reaction (PCR)
- 5.1.3. In-situ Hybridization (ISH)
- 5.1.4. Gene Sequencing
- 5.1.5. Other Technologies
- 5.2. Market Analysis, Insights and Forecast - by Indication
- 5.2.1. Lung Cancer
- 5.2.2. Breast Cancer
- 5.2.3. Colorectal Cancer
- 5.2.4. Leukemia
- 5.2.5. Melanoma
- 5.2.6. Other Indications
- 5.3. Market Analysis, Insights and Forecast - by Region
- 5.3.1. Germany
- 5.3.2. United Kingdom
- 5.3.3. France
- 5.3.4. Italy
- 5.3.5. Spain
- 5.3.6. Rest of Europe
- 5.1. Market Analysis, Insights and Forecast - by Technology
- 6. Germany Europe Companion Diagnostics Market Analysis, Insights and Forecast, 2019-2031
- 6.1. Market Analysis, Insights and Forecast - by Technology
- 6.1.1. Immunohistochemistry (IHC)
- 6.1.2. Polymerase Chain Reaction (PCR)
- 6.1.3. In-situ Hybridization (ISH)
- 6.1.4. Gene Sequencing
- 6.1.5. Other Technologies
- 6.2. Market Analysis, Insights and Forecast - by Indication
- 6.2.1. Lung Cancer
- 6.2.2. Breast Cancer
- 6.2.3. Colorectal Cancer
- 6.2.4. Leukemia
- 6.2.5. Melanoma
- 6.2.6. Other Indications
- 6.1. Market Analysis, Insights and Forecast - by Technology
- 7. United Kingdom Europe Companion Diagnostics Market Analysis, Insights and Forecast, 2019-2031
- 7.1. Market Analysis, Insights and Forecast - by Technology
- 7.1.1. Immunohistochemistry (IHC)
- 7.1.2. Polymerase Chain Reaction (PCR)
- 7.1.3. In-situ Hybridization (ISH)
- 7.1.4. Gene Sequencing
- 7.1.5. Other Technologies
- 7.2. Market Analysis, Insights and Forecast - by Indication
- 7.2.1. Lung Cancer
- 7.2.2. Breast Cancer
- 7.2.3. Colorectal Cancer
- 7.2.4. Leukemia
- 7.2.5. Melanoma
- 7.2.6. Other Indications
- 7.1. Market Analysis, Insights and Forecast - by Technology
- 8. France Europe Companion Diagnostics Market Analysis, Insights and Forecast, 2019-2031
- 8.1. Market Analysis, Insights and Forecast - by Technology
- 8.1.1. Immunohistochemistry (IHC)
- 8.1.2. Polymerase Chain Reaction (PCR)
- 8.1.3. In-situ Hybridization (ISH)
- 8.1.4. Gene Sequencing
- 8.1.5. Other Technologies
- 8.2. Market Analysis, Insights and Forecast - by Indication
- 8.2.1. Lung Cancer
- 8.2.2. Breast Cancer
- 8.2.3. Colorectal Cancer
- 8.2.4. Leukemia
- 8.2.5. Melanoma
- 8.2.6. Other Indications
- 8.1. Market Analysis, Insights and Forecast - by Technology
- 9. Italy Europe Companion Diagnostics Market Analysis, Insights and Forecast, 2019-2031
- 9.1. Market Analysis, Insights and Forecast - by Technology
- 9.1.1. Immunohistochemistry (IHC)
- 9.1.2. Polymerase Chain Reaction (PCR)
- 9.1.3. In-situ Hybridization (ISH)
- 9.1.4. Gene Sequencing
- 9.1.5. Other Technologies
- 9.2. Market Analysis, Insights and Forecast - by Indication
- 9.2.1. Lung Cancer
- 9.2.2. Breast Cancer
- 9.2.3. Colorectal Cancer
- 9.2.4. Leukemia
- 9.2.5. Melanoma
- 9.2.6. Other Indications
- 9.1. Market Analysis, Insights and Forecast - by Technology
- 10. Spain Europe Companion Diagnostics Market Analysis, Insights and Forecast, 2019-2031
- 10.1. Market Analysis, Insights and Forecast - by Technology
- 10.1.1. Immunohistochemistry (IHC)
- 10.1.2. Polymerase Chain Reaction (PCR)
- 10.1.3. In-situ Hybridization (ISH)
- 10.1.4. Gene Sequencing
- 10.1.5. Other Technologies
- 10.2. Market Analysis, Insights and Forecast - by Indication
- 10.2.1. Lung Cancer
- 10.2.2. Breast Cancer
- 10.2.3. Colorectal Cancer
- 10.2.4. Leukemia
- 10.2.5. Melanoma
- 10.2.6. Other Indications
- 10.1. Market Analysis, Insights and Forecast - by Technology
- 11. Rest of Europe Europe Companion Diagnostics Market Analysis, Insights and Forecast, 2019-2031
- 11.1. Market Analysis, Insights and Forecast - by Technology
- 11.1.1. Immunohistochemistry (IHC)
- 11.1.2. Polymerase Chain Reaction (PCR)
- 11.1.3. In-situ Hybridization (ISH)
- 11.1.4. Gene Sequencing
- 11.1.5. Other Technologies
- 11.2. Market Analysis, Insights and Forecast - by Indication
- 11.2.1. Lung Cancer
- 11.2.2. Breast Cancer
- 11.2.3. Colorectal Cancer
- 11.2.4. Leukemia
- 11.2.5. Melanoma
- 11.2.6. Other Indications
- 11.1. Market Analysis, Insights and Forecast - by Technology
- 12. Germany Europe Companion Diagnostics Market Analysis, Insights and Forecast, 2019-2031
- 13. United Kingdom Europe Companion Diagnostics Market Analysis, Insights and Forecast, 2019-2031
- 14. France Europe Companion Diagnostics Market Analysis, Insights and Forecast, 2019-2031
- 15. Italy Europe Companion Diagnostics Market Analysis, Insights and Forecast, 2019-2031
- 16. Spain Europe Companion Diagnostics Market Analysis, Insights and Forecast, 2019-2031
- 17. Rest of Europe Europe Companion Diagnostics Market Analysis, Insights and Forecast, 2019-2031
- 18. Competitive Analysis
- 18.1. Market Share Analysis 2024
- 18.2. Company Profiles
- 18.2.1 Thermo Fisher Scientific Inc *List Not Exhaustive
- 18.2.1.1. Overview
- 18.2.1.2. Products
- 18.2.1.3. SWOT Analysis
- 18.2.1.4. Recent Developments
- 18.2.1.5. Financials (Based on Availability)
- 18.2.2 BioMerieux SA
- 18.2.2.1. Overview
- 18.2.2.2. Products
- 18.2.2.3. SWOT Analysis
- 18.2.2.4. Recent Developments
- 18.2.2.5. Financials (Based on Availability)
- 18.2.3 Siemens Healthineers
- 18.2.3.1. Overview
- 18.2.3.2. Products
- 18.2.3.3. SWOT Analysis
- 18.2.3.4. Recent Developments
- 18.2.3.5. Financials (Based on Availability)
- 18.2.4 Abbott Laboratories
- 18.2.4.1. Overview
- 18.2.4.2. Products
- 18.2.4.3. SWOT Analysis
- 18.2.4.4. Recent Developments
- 18.2.4.5. Financials (Based on Availability)
- 18.2.5 Qiagen Inc
- 18.2.5.1. Overview
- 18.2.5.2. Products
- 18.2.5.3. SWOT Analysis
- 18.2.5.4. Recent Developments
- 18.2.5.5. Financials (Based on Availability)
- 18.2.6 F Hoffmann-La Roche AG
- 18.2.6.1. Overview
- 18.2.6.2. Products
- 18.2.6.3. SWOT Analysis
- 18.2.6.4. Recent Developments
- 18.2.6.5. Financials (Based on Availability)
- 18.2.7 Beckman Coulter Inc (Danaher Corporation)
- 18.2.7.1. Overview
- 18.2.7.2. Products
- 18.2.7.3. SWOT Analysis
- 18.2.7.4. Recent Developments
- 18.2.7.5. Financials (Based on Availability)
- 18.2.8 Agilent Technologies
- 18.2.8.1. Overview
- 18.2.8.2. Products
- 18.2.8.3. SWOT Analysis
- 18.2.8.4. Recent Developments
- 18.2.8.5. Financials (Based on Availability)
- 18.2.1 Thermo Fisher Scientific Inc *List Not Exhaustive
List of Figures
- Figure 1: Europe Companion Diagnostics Market Revenue Breakdown (Million, %) by Product 2024 & 2032
- Figure 2: Europe Companion Diagnostics Market Share (%) by Company 2024
List of Tables
- Table 1: Europe Companion Diagnostics Market Revenue Million Forecast, by Region 2019 & 2032
- Table 2: Europe Companion Diagnostics Market Volume K Units Forecast, by Region 2019 & 2032
- Table 3: Europe Companion Diagnostics Market Revenue Million Forecast, by Technology 2019 & 2032
- Table 4: Europe Companion Diagnostics Market Volume K Units Forecast, by Technology 2019 & 2032
- Table 5: Europe Companion Diagnostics Market Revenue Million Forecast, by Indication 2019 & 2032
- Table 6: Europe Companion Diagnostics Market Volume K Units Forecast, by Indication 2019 & 2032
- Table 7: Europe Companion Diagnostics Market Revenue Million Forecast, by Region 2019 & 2032
- Table 8: Europe Companion Diagnostics Market Volume K Units Forecast, by Region 2019 & 2032
- Table 9: Europe Companion Diagnostics Market Revenue Million Forecast, by Country 2019 & 2032
- Table 10: Europe Companion Diagnostics Market Volume K Units Forecast, by Country 2019 & 2032
- Table 11: Germany Europe Companion Diagnostics Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 12: Germany Europe Companion Diagnostics Market Volume (K Units) Forecast, by Application 2019 & 2032
- Table 13: United Kingdom Europe Companion Diagnostics Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 14: United Kingdom Europe Companion Diagnostics Market Volume (K Units) Forecast, by Application 2019 & 2032
- Table 15: France Europe Companion Diagnostics Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 16: France Europe Companion Diagnostics Market Volume (K Units) Forecast, by Application 2019 & 2032
- Table 17: Italy Europe Companion Diagnostics Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 18: Italy Europe Companion Diagnostics Market Volume (K Units) Forecast, by Application 2019 & 2032
- Table 19: Spain Europe Companion Diagnostics Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 20: Spain Europe Companion Diagnostics Market Volume (K Units) Forecast, by Application 2019 & 2032
- Table 21: Rest of Europe Europe Companion Diagnostics Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 22: Rest of Europe Europe Companion Diagnostics Market Volume (K Units) Forecast, by Application 2019 & 2032
- Table 23: Europe Companion Diagnostics Market Revenue Million Forecast, by Technology 2019 & 2032
- Table 24: Europe Companion Diagnostics Market Volume K Units Forecast, by Technology 2019 & 2032
- Table 25: Europe Companion Diagnostics Market Revenue Million Forecast, by Indication 2019 & 2032
- Table 26: Europe Companion Diagnostics Market Volume K Units Forecast, by Indication 2019 & 2032
- Table 27: Europe Companion Diagnostics Market Revenue Million Forecast, by Country 2019 & 2032
- Table 28: Europe Companion Diagnostics Market Volume K Units Forecast, by Country 2019 & 2032
- Table 29: Europe Companion Diagnostics Market Revenue Million Forecast, by Technology 2019 & 2032
- Table 30: Europe Companion Diagnostics Market Volume K Units Forecast, by Technology 2019 & 2032
- Table 31: Europe Companion Diagnostics Market Revenue Million Forecast, by Indication 2019 & 2032
- Table 32: Europe Companion Diagnostics Market Volume K Units Forecast, by Indication 2019 & 2032
- Table 33: Europe Companion Diagnostics Market Revenue Million Forecast, by Country 2019 & 2032
- Table 34: Europe Companion Diagnostics Market Volume K Units Forecast, by Country 2019 & 2032
- Table 35: Europe Companion Diagnostics Market Revenue Million Forecast, by Technology 2019 & 2032
- Table 36: Europe Companion Diagnostics Market Volume K Units Forecast, by Technology 2019 & 2032
- Table 37: Europe Companion Diagnostics Market Revenue Million Forecast, by Indication 2019 & 2032
- Table 38: Europe Companion Diagnostics Market Volume K Units Forecast, by Indication 2019 & 2032
- Table 39: Europe Companion Diagnostics Market Revenue Million Forecast, by Country 2019 & 2032
- Table 40: Europe Companion Diagnostics Market Volume K Units Forecast, by Country 2019 & 2032
- Table 41: Europe Companion Diagnostics Market Revenue Million Forecast, by Technology 2019 & 2032
- Table 42: Europe Companion Diagnostics Market Volume K Units Forecast, by Technology 2019 & 2032
- Table 43: Europe Companion Diagnostics Market Revenue Million Forecast, by Indication 2019 & 2032
- Table 44: Europe Companion Diagnostics Market Volume K Units Forecast, by Indication 2019 & 2032
- Table 45: Europe Companion Diagnostics Market Revenue Million Forecast, by Country 2019 & 2032
- Table 46: Europe Companion Diagnostics Market Volume K Units Forecast, by Country 2019 & 2032
- Table 47: Europe Companion Diagnostics Market Revenue Million Forecast, by Technology 2019 & 2032
- Table 48: Europe Companion Diagnostics Market Volume K Units Forecast, by Technology 2019 & 2032
- Table 49: Europe Companion Diagnostics Market Revenue Million Forecast, by Indication 2019 & 2032
- Table 50: Europe Companion Diagnostics Market Volume K Units Forecast, by Indication 2019 & 2032
- Table 51: Europe Companion Diagnostics Market Revenue Million Forecast, by Country 2019 & 2032
- Table 52: Europe Companion Diagnostics Market Volume K Units Forecast, by Country 2019 & 2032
- Table 53: Europe Companion Diagnostics Market Revenue Million Forecast, by Technology 2019 & 2032
- Table 54: Europe Companion Diagnostics Market Volume K Units Forecast, by Technology 2019 & 2032
- Table 55: Europe Companion Diagnostics Market Revenue Million Forecast, by Indication 2019 & 2032
- Table 56: Europe Companion Diagnostics Market Volume K Units Forecast, by Indication 2019 & 2032
- Table 57: Europe Companion Diagnostics Market Revenue Million Forecast, by Country 2019 & 2032
- Table 58: Europe Companion Diagnostics Market Volume K Units Forecast, by Country 2019 & 2032
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Europe Companion Diagnostics Market?
The projected CAGR is approximately 9.23%.
2. Which companies are prominent players in the Europe Companion Diagnostics Market?
Key companies in the market include Thermo Fisher Scientific Inc *List Not Exhaustive, BioMerieux SA, Siemens Healthineers, Abbott Laboratories, Qiagen Inc, F Hoffmann-La Roche AG, Beckman Coulter Inc (Danaher Corporation), Agilent Technologies.
3. What are the main segments of the Europe Companion Diagnostics Market?
The market segments include Technology, Indication.
4. Can you provide details about the market size?
The market size is estimated to be USD 1.29 Million as of 2022.
5. What are some drivers contributing to market growth?
Rising Demand for Personalized Medicine and Targeted Therapy; Rise in Biomarker Discovery; Rising Prevalence of Chronic Diseases.
6. What are the notable trends driving market growth?
Immunohistochemistry Segment is Estimated to Register Significant Growth over the Forecast Period..
7. Are there any restraints impacting market growth?
High Cost of Drug Development and Associated Clinical Trials; High Reimbursement Issues Associated with Personalized Medicines.
8. Can you provide examples of recent developments in the market?
August 2022: BD (Becton, Dickinson, and Company) announced a collaboration agreement with Labcorp for creating a framework to develop, manufacture, market, and commercialize flow cytometry-based companion diagnostics (CDx) intended to match patients with life-changing treatments for cancer and other diseases.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million and volume, measured in K Units.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Europe Companion Diagnostics Market," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Europe Companion Diagnostics Market report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Europe Companion Diagnostics Market?
To stay informed about further developments, trends, and reports in the Europe Companion Diagnostics Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database



Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)

Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations

Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence